Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

The phase 3 CALLA trial of durvalumab plus chemoradiotherapy versus chemoradiotherapy alone in 770 women with locally advanced cervical cancer did not significantly improve investigator-assessed PFS in a biomarker-unselected population (HR 0.84, 95% CI 0.65–1.08, P=0.17).

Lancet OncolPubMed 38039991DOI 10.1016/S1470-2045(23)00479-5